Second-line Anti-Tuberculosis Drugs and Risk of Alopecia: A Retrospective Cohort study
Alopecia is not a well-known adverse effect of second-line anti-tuberculosis drugs. It is, however, been frequently reported in Eritrea and 83% of the reports of alopecia associated with second-line anti-TB drugs in the global adverse drug reaction database, as of July 25, 2017, were submitted from Eritrea. It is wondering why this much variation is happening and this study is therefore aimed at quantifying the risk, identifying possible risk factors and elucidating the causal association between alopecia and the second-line anti-TB drugs in Eritrea. This was an observational cohort study of PLWH on IPT enrolled from three Antiretroviral therapy (ART) Clinics in Eritrea. Causality and preventability of the cases were assessed using Naranjo probability scale and P-method respectively.